Leukocyte Lysozyme and Unsaturated Vitamin B12 Binding Protein Content in Chronic Myeloproliferative Disease: Demonstration of an Altered Ratio in Chronic Myelocytic Leukemia

Lysozyme ◽  
1974 ◽  
pp. 355-358
Author(s):  
HARRIET S. GILBERT
Blood ◽  
1958 ◽  
Vol 13 (8) ◽  
pp. 740-747 ◽  
Author(s):  
ROBERT S. MENDELSOHN ◽  
DONALD M. WATKIN ◽  
ANN P. HORBETT ◽  
JOHN L. FAHEY

Abstract Vitamin B12-binding proteins in the serum of normal subjects and of patients with chronic myelocytic leukemia have been compared. The in-vivo-bound B12 was utilized to identify the binding protein. Column protein chromatography and block and paper electrophoresis were employed individually and in combination to characterize the B12-binding protein. B12 was found to be bound primarily to an alpha-l globulin in both normal individuals and in patients with chronic myelocytic leukemia. No qualitative difference was found in these proteins. The increased amounts of B12-binding protein in the serum of patients with chronic myelocytic leukemia would seem to be attributable to abnormal metabolism of the same protein that binds B12 in normal serum.


Blood ◽  
1962 ◽  
Vol 19 (2) ◽  
pp. 229-235 ◽  
Author(s):  
LEO M. MEYER ◽  
EUGENE P. CRONKITE ◽  
INEZ F. MILLER ◽  
CLAIRE W MULZAC ◽  
IRVING JONES

Abstract 1. Mature neutrophilic leukocytes show the highest Co60B12 binding capacity. 2. Less mature granulocytes, "blast" forms and eosinophils have little or no Co60B12 binding capacity. 3. Disintegrated mature leukocytes from chronic myelocytic leukemia and polycythemia vera show higher B12 binding capacity than intact cells. 4. Mature leukocytes from patients with chronic myelocytic leukemia and polycythemia vera show a two-phase B12 curve suggesting specific and nonspecific binding, similar to that observed in human serum. 5. Disintegration products from mature neutrophilic leukocytes probably contribute largely to increased B12 binding capacity of serum in chronic myelocytic leukemia and polycythemia vera.


Introduction. CML is the most common form of chronic leukemia in Indonesia, whereas in Western countries it is more commonly found in the form of chronic lymphocytic leukemia (CLL). Chronic myelocytic leukemia (CML) is a chronic myeloproliferative disease with clonal abnormalities due to genetic changes in stem cell pluripotence. This disease is characterized by proliferation of granulocyte series without differentiation disorders. On the CML, the Philadelphia chromosome (Ph1 chr) is found in a reciprocal translocation 9.22 (t9; 22). Insulin-like Growth Factor-1 is a natural polypeptide in the human body that has similarities with insulin. IGF-1 plays an important role in the growth and development of tissues. As such, several studies have shown an association between IGF-1 and -2 circulation rates. IGF-1 plays an important role in terms of stimulating cell proliferation and inhibition of apoptosis. This affects the regulation of the body's physiological growth as well as pathological growth such as cancer. Until now there has been no research on IGF-1 levels in CML patients with imatinib and nilotinib treatment. Methods. This research is a cross-sectional study, by observing the status of exposure and simultaneous disease in individuals from a single population, in one period. The study was conducted in December 2019 at the Outpatient Clinic of H Adam Malik General Hospital Medan with the approval of the North Sumatera University Research Ethics Commission. Data were analyzed using SPSS where p <0.05 was considered significant. Results. This study showed that there were no differences in IGF-1 levels between CML patients who received imatinib and nilotinib therapy. The mean IGF-1 results were obtained in the imatinib group 107.43±19.70 and nilotinib 107.43±18.09. While the healthy population is 138.60±52.85. Conclusion. No significant differences were found in IGF-1 levels between CML patients receiving imatinib and nilotinib therapy with healthy populations.


Blood ◽  
1959 ◽  
Vol 14 (3) ◽  
pp. 274-278 ◽  
Author(s):  
V. M. DOCTOR ◽  
D. E. BERGSAGEL ◽  
C. C. SHULLENBERGER

Abstract Serum vitamin B12 determinations and the total leukocyte counts were made at regular intervals in chronic myelocytic leukemia patients before, during and after therapy with 6-MP or Myleran. The results indicate that a reduction in total leukocytes following therapy is followed by a gradual lowering of serum vitamin B12. The levels of serum vitamin B12 at the completion of therapy may be related to the duration of remission.


Blood ◽  
1960 ◽  
Vol 15 (5) ◽  
pp. 646-661 ◽  
Author(s):  
EUGENE A. BRODY ◽  
SOLOMON ESTREN ◽  
LOUIS R. WASSERMAN

Abstract 1. Studies of the fate of intravenously injected radioactive vitamin B12 have been performed in patients with normal, low and high serum concentrations of vitamin B12. 2. Abnormal plasma disappearance curves were noted in chronic myelocytic leukemia, pernicious anemia in relapse and in remission, total gastrectomy and malabsorption syndrome. 3. In chronic myelocytic leukemia, the slow clearance of plasma radioactivity may be explained by the increased binding capacity of the plasma proteins for vitamin B12. 4. Plasma clearance of radioactivity is slower than normal in pernicious anemia, even in remission. The failure of the disappearance curve to return to normal in pernicious anemia in complete remission suggests the existence of a plasma "B12-transferase," whose function is to transfer circulating B12 to the tissues. The disappearance curves suggest that the amount of such "B12-transferase" is diminished in pernicious anemia, total gastrectomy and certain Cases of malabsorption syndrome. 5. A relationship between a hypothetical "B12-transferase" and intrinsic factor is discussed.


Blood ◽  
1972 ◽  
Vol 40 (4) ◽  
pp. 542-549 ◽  
Author(s):  
Ralph Carmel ◽  
Victor Herbert

Abstract Much evidence suggests that granulocytes are a major source of serum vitamin B12-binding protein (BBP). The latter has three components: α-1-globulin BBP (Transcobalamin I, TC I), β-globulin BBP (TC II), and a recently described third BBP. Granulocytic BBP has appeared to be identical to TC I except in electrophoretic mobility. In the present study, the dominant BBP of leukocyte extracts from subjects with and without myeloproliferative disease behaved like the third serum BBP. With a few exceptions, more than half the leukocytic binder eluted with the "β globulins" on rapid DEAE-cellulose chromatography. At pH 8.6, electrophoretic mobility of the leukocytic BBP was always α2 or β. At ph 4.5, normal and chronic myelogenous leukemia leukocytic BBP, unlike TC I and TC II, showed little electrophoretic migration. These findings suggest that leukocytic BBP is probably heterogenous and that its major component resembles the third serum BBP more than it does TC I. The third serum BBP, levels of which are elevated in some states of leukocytic proliferation, may derive directly from mature granulocytes. TC I may arise by addition of sialic acid to the third (granulocytic) BBP under certain circumstances or be released from other cells, such as less mature granulocytes. Much of the confusion in the literature regarding source and significance of serum BBP may relate to separating it into only two fractions (α globulin and "β globulin," or "TC I" and TC II) instead of into three fractions.


Blood ◽  
1956 ◽  
Vol 11 (1) ◽  
pp. 31-43 ◽  
Author(s):  
D. L. MOLLIN ◽  
W. R. PITNEY ◽  
S. J. BAKER ◽  
J. E. BRADLEY

Abstract Intravenous injections of 1.5 µg. of 58Co B12 were given to subjects with normal serum B12 concentrations, to patients with vitamin B12 deficiency and to patients with chronic myelocytic leukemia. The rate of plasma clearance of radioactivity after this dose was slowest in patients with chronic myelocytic leukemia and patients with pernicious anemia in severe relapse. In patients with vitamin B12 deficiency, serum B12 concentrations were estimated microbiologically at frequent intervals after the injection. There was a good correlation between the results obtained by microbiological assay and as calculated from plasma radioactivity. Significant differences were not observed between the urinary excretion of radioactivity by normal subjects and patients with B12 deficiency.


Sign in / Sign up

Export Citation Format

Share Document